NCT04270864 2024-10-18
PRIMO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Terminated
Clinical Trials
7 trialsNCT04196283 2023-02-27
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
AbbVie
Phase 1 Completed
NCT03445533 2022-11-08
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Idera Pharmaceuticals, Inc.
Phase 3 Terminated
NCT02644967 2022-08-03
ILLUMINATE-204
Idera Pharmaceuticals, Inc.
Phase 2 Completed
NCT03865082 2022-02-17
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Idera Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT04126876 2021-04-15
INTRIM
Amsterdam UMC, location VUmc
Phase 2 Recruiting
NCT03052205 2020-02-11
ILLUMINATE-101
Idera Pharmaceuticals, Inc.
Phase 1 Completed